Effect of anabolic implants on beef intramuscular lipid content.
(17/2488)
Sixty ribeye steaks were used to determine the effects of anabolic implants on i.m. lipid composition of beef steers. Steaks were obtained from carcasses (346 kg) of steers assigned to four treatment groups (C = nonimplanted control; ET = 28 mg of estradiol benzoate plus 200 mg of trenbolone acetate on d 0; ET/ET = ET on d 0 and d 61; and S/ET = 20 mg of estradiol benzoate plus 200 mg of progesterone on d 0 and ET on d 61) and fed a high-concentrate diet for 127 d. Total fatty acid content of the longissimus was less (P < .05) for implanted steers. Implanting increased (P < .05) stearic and linolenic acid percentages and reduced (P < .05) oleic acid percentage but did not alter (P > .05) percentages of other fatty acids. These changes translated into increased (P < .05) percentages of saturated fatty acids and reduced (P < .05) monounsaturated fatty acids in the longissimus of implanted steers. However, on a per-steak weight basis, implanting did not alter (P > .05) the amounts of any of the individual fatty acids, but it increased (P < .05) the total cholesterol amount. Implanting with an estrogenic compound first reduced (P < .05) the percentage and total amounts of linoleic and polyunsaturated fatty acids. On a percentage basis, implanting alters fatty acid amounts; however, when the increase in ribeye size with implanting is accounted for and fatty acids are evaluated on a per-steak basis, these differences are not significant. (+info)
Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug.
(18/2488)
PURPOSE: To determine intraocular toxicity and efficacy of the lipid prodrug of foscarnet, 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA), as a long-acting, nontoxic intravitreous injectable drug delivery system for cytomegalovirus (CMV) retinitis. METHODS: ODG-PFA was synthesized by coupling the phosphonate residue of PFA to the 3 hydroxyl of 1-O-octadecyl-sn-glycerol and formulated as micelles and liposomes at concentrations so that, after injection into the rabbit vitreous, the resultant intravitreal concentrations were 0.2 mM, 0.63 mM, and 2 mM in micellar formulation and 0.02 mM, 0.063 mM, 0.2 mM, and 0.63 mM for liposomal formulation. The compounds were injected, and toxicology evaluations were performed. RESULTS: Intravitreal injections of micellar ODG-PFA resulted in aggregation of the material in vitreous and variable local retinal damage. Intravitreal injections of the liposomal ODG-PFA revealed even dispersion of the compounds and a clear vitreous, using final concentration in the vitreous of 0.2 mM. No intraocular toxicity was found with the 0.632 mM final concentration. The 50% inhibitory concentration (IC50) for CMV of ODG-PFA was 0.43+/-0.27 microM, and the therapeutic index of ODG-PFA after intravitreal injection was estimated to be 1470:1. CONCLUSIONS: Lipid-derivatized foscarnet liposome formulations may be a useful long-acting delivery system for the therapy of CMV retinitis. (+info)
Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis.
(19/2488)
AIMS: A new formulation, low dose microencapsulated aspirin, permits slow absorption of aspirin and presystemic acetylation of platelet cyclo-oxygenase within the portal circulation, potentially avoiding deleterious effects on gastric and systemic prostaglandin synthesis. The objective of this study was to determine whether the administration of microencapsulated aspirin was as effective as enteric coated (EC) aspirin as an inhibitor of platelet function in patients with atherosclerosis. METHODS: One hundred and four patients were enrolled and randomised after a run in period of at least 14 days on aspirin EC 75 mg (day 0), to receive either microencapsulated aspirin 162.5 mg (n=34), aspirin EC 150 mg (n=36) or continue on aspirin EC 75 mg (n=34) for 28 days. Serum thromboxane B2 and collagen-induced platelet aggregation and release of 5-hydroxytryptamine (EC50 values) were measured on days 0 and 28. Aggregation/release EC50s were then repeated in the presence of a large dose of aspirin added in vitro to determine the EC50 at the maximum level of platelet inhibition. RESULTS: Median thromboxane B2 levels were low after 14 days run-in therapy with aspirin EC 75 mg, but significant further reductions were seen on day 28 in patients randomised to microencapsulated aspirin 162.5 mg (P=0.0368) and aspirin EC 150 mg (P=0.0004) compared with those remaining on aspirin EC 75 mg. Median EC50 s on day 28 showed small but significant increases from baseline (day 0) in aggregation in patients randomised to microencapsulated aspirin 162.5 mg (0.62-0.85, P=0.0482) and in both aggregation and release in patients randomised to aspirin EC 150 mg (0.95-1.20, P=0.0002, 8.4-11.7, P<0. 0001, respectively) signifying enhanced antiplatelet activity. No changes were seen in patients continuing on aspirin EC 75 mg. Results following addition of high dose aspirin in vitro suggest that mechanisms other than thromboxane synthesis may be operative in the long term effects of microencapsulated aspirin 162.5 mg and aspirin EC 150 mg over aspirin EC 75 mg. CONCLUSIONS: The results show good inhibition of thromboxane B2 synthesis and subsequent platelet activity by all preparations of aspirin, although both microencapsulated aspirin 162.5 mg and aspirin EC 150 mg are slightly more effective than aspirin EC 75 mg. A randomised trial is now required to determine whether microencapsulated aspirin is associated with fewer gastric side-effects. (+info)
New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin.
(20/2488)
Insulin is a short-lived species in the circulatory system. After binding to its receptor sites and transmission of its biological signals, bound insulin undergoes receptor-mediated endocytosis and consequent degradation. An inactive insulin derivative that is not recognized by the receptor has a longer circulation life, but obviously is biologically impotent. (Fmoc)2 insulin is an insulin derivative purified through high-performance liquid chromatography in which two 9-fluorenylmethoxycarbonyl (Fmoc) moieties are covalently linked to the (alpha-amino group of phenylalanine B1 and the epsilon-amino group of lysine B29. It has 1-2% of the biological potency and receptor binding capacity of the native hormone. After incubation, (Fmoc)2 insulin undergoes a time-dependent spontaneous conversion to fully active insulin in aqueous solution at 37 degrees C and a pH range of 7-8.5. At pH 7.4, the conversion proceeds slowly (t1/2 = 12 +/- 1 days) and biological activity is generated gradually. A single subcutaneous administration of (Fmoc)2 insulin to streptozocin-treated diabetic rats normalized their blood glucose levels and maintained the animals in an anabolic state over 2-3 days. A broad shallow peak of immunoreactive insulin was found to persist in circulation over this period. To confirm further that the long-acting effect of (Fmoc)2 insulin proceeds via slow release in the blood circulation itself, we administered native insulin, NPH insulin, or the (Fmoc)2 derivative intraperitoneally. The rats recovered from hypoglycemia at t1/2 = 8.0 +/- 0.3 and 10 +/- 0.4 h after administration of native and NPH insulin, respectively. In contrast, (Fmoc)2 insulin was active for a significantly longer time, with an extended onset of t1/2 = 26 +/- 1h, and a glucose-lowering effect even 40 h after administration. (Fmoc)2 insulin was also found to be more resistant to proteolysis. Finally, we found that (Fmoc)2 insulin does not induce antigenic effects. In summary, we present here a new concept for prolonging the half-life of insulin in the circulatory system, in which receptor-mediated endocytosis and degradation is delayed and accompanied by a time-dependent generation of basal insulin. (+info)
Performance and digestibilities of beef cattle fed diets supplemented with either soybean meal or roasted soybeans and implanted with Synovex.
(21/2488)
Two 160-d feedlot experiments, each consisting of 20 Angus-Hereford steers (216 +/- 5 kg BW, Exp. 1; 258 +/- 5 kg BW, Exp. 2) and 20 Angus-Hereford heifers (208 +/- 5 kg BW, Exp. 1; 236 +/- 5 kg BW, Exp. 2), were used to investigate the effects of supplementing diets with either roasted soybeans (RSB, roasted at 127 degrees C for 10 min) or soybean meal (SBM) and implanting or not implanting with an estrogenic growth promoter (SYN; Synovex-S, 20 mg of estradiol benzoate plus 200 mg of progesterone or Synovex-H, 20 mg of estradiol benzoate plus 200 mg of testosterone) on performance. The cattle were fed a basal diet of 15% orchardgrass silage, 15% corn silage, and 70% corn-based concentrate. Treatments were 1) no SYN and fed a SBM-supplemented diet, 2) no SYN and fed a RSB-supplemented diet, 3) SYN and SBM, and 4) SYN and RSB. Cattle in the SYN groups were reimplanted at 80 d. Four additional Angus-Hereford steers were used in a digestion and nitrogen balance experiment conducted during the first half of Exp. 1. For the total 160-d feedlot experiments, DMI for RSB compared with SBM was lower (P < .01; 8.5 vs 9.2 kg/d, SEM = .07) and ADG/DMI tended to be higher (P < .10; 165 vs 157 g/kg, SEM = 1.3). Final BW of steers fed RSB was similar (P > .10) to that of steers fed SBM (473 vs 478 kg, SEM = 5.6), as was ADG (1.39 vs 1.43 kg/d, SEM = .02). Dry matter intake for SYN-implanted steers was higher (P < .01) than for steers not implanted (9.2 vs 8.5 kg/d). Likewise, final BW (491 vs 460 kg) and ADG (1.49 vs 1.33 kg/d) were higher (P < .01), and ADG/DMI (166 vs 157 g/kg) tended to be higher (P < .10), for SYN-implanted steers than for steers not implanted. During the more rapid muscle growth period (0 to 80 d), DMI for RSB compared with SBM was lower (P < .01; 7.8 vs 8.6 kg/d, SEM = .07) and ADG/DMI was similar (P > .10; 181 vs 172 g/kg, SEM = 1.8). Dry matter intake for SYN-implanted steers was higher (P < .05) than for steers not implanted (8.4 vs 8.0 kg/d), as was ADG/DMI (P < .01, 182 vs 171 g/kg). During this more rapid growth period, the supplement x implant interaction for ADG was significant (P < .05; 1.35, 1.36, 1.59, and 1.44 kg/d for Treatments 1, 2, 3, and 4, respectively, SEM = .04). There were no differences in digestibilities or N balance. The results suggest that there is no improvement in performance under feedlot conditions when RSB replaces SBM in the diet of beef cattle, and, in young cattle, RSB may reduce the response expected by an estrogenic growth promoter. (+info)
The effect of roasted soybeans in the diet of feedlot steers and Synovex-S ear implants on carcass characteristics and estimated composition.
(22/2488)
Beef steer carcasses from three 2 x 2 factorial feeding experiments (Exp. 1, 20 carcasses; Exp. 2 and 3, 19 carcasses each) were evaluated to study the influence of supplementing with roasted soybeans (RSB; 127 degrees C for 10 min) vs soybean meal (SBM) and implanting with the estrogenic growth promoter Synovex-S (SYN, 20 mg estradiol benzoate and 200 mg progesterone) on carcass merit, composition of dissected 9-10-11th rib section, estimated edible carcass composition, and cooking characteristics of strip loin steaks. In all experiments, steers were fed diets consisting of 15% corn silage, 15% orchardgrass silage, and 70% corn-based concentrate. There were no treatment interactions found in this study. Final BW averaged 480.4, 498.5, and 500.7 kg for Exp. 1, 2, and 3, respectively, and hot carcass weights averaged 288.4, 296.4, and 309.1 kg. Across experiments, hot carcass weight was 8.3 kg less (P < .03) for RSB steers than for SBM steers. Fat weight (P < .01) and percentage of fat (P < .01) were less and percentage of bone (P < .04) was greater in the 9-10-11th rib section of RSB steers than of SBM steers. Estimated percentage of fat (P < .02) was less and percentage of bone (P < .04) was greater in edible carcass of RSB steers than in that of SBM steers. Total 9-10-11th rib section weight tended to be less for RSB steers (P < .08) than for SBM steers. Carcass merit measurements were not affected (P > .10) by supplement, but numerically the percentage of kidney, pelvic, and heart fat was 11% greater for RSB steers than for SBM steers in Exp. 2 and 3. Final BW and carcass weight were 38.7 and 22.6 kg greater (P < .01), respectively, for SYN-implanted steers than for steers not implanted. Longissimus muscle area was greater (P < .01), percentage of kidney, pelvic, and heart fat (P < .02) was less, USDA quality grade tended to be less (P < .09), and shear force of strip loin was greater (P < .01) for SYN-implanted steers than for steers not implanted. The 9-10-11th rib section and estimated carcass compositions were not different (P > .10) between SYN-implanted steers and steers not implanted but reflected a somewhat leaner carcass. The authors conclude from this study that in feedlot steers, either implanted or not implanted, there is no benefit from supplementing with RSB in place of SBM, and that the use of RSB in place of SBM in feedlot diets may reduce the amount of edible carcass. (+info)
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.
(23/2488)
PURPOSE: To evaluate the efficacy and safety of a slow-release formulation of cytarabine (DepoCyt; Chiron Corp, Emeryville, CA, and Skye Pharma, Inc, San Diego, CA) that maintains cytotoxic concentrations of cytarabine (ara-C) in the CSF of most patients for more than 14 days. PATIENTS AND METHODS: Twenty-eight patients with lymphoma and a positive CSF cytology were randomized to receive DepoCyt 50 mg once every 2 weeks or free ara-C 50 mg twice a week for 1 month. Patients whose CSF cytology converted to negative and who did not have neurologic progression received an additional 3 months of consolidation therapy and then 4 months of maintenance therapy. All patients received dexamethasone 4 mg orally bid on days 1 through 5 of each 2-week cycle. RESULTS: The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006). All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen. Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05). DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041). The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease. CONCLUSION: DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week. (+info)
The influence of frusemide formulation on diuretic effect and efficiency.
(24/2488)
AIMS: Changes in drug delivery rate may result in clinically important changes in drug effects. For the loop diuretic frusemide, it would be desirable to develop controlled release preparations, that could maintain an effective urinary excretion rate over a prolonged period of time. The aim of this study was to investigate the influence of frusemide formulation on frusemide recovery, diuretic effect and efficiency. METHODS: Twelve subjects were given 60 mg of four different frusemide controlled release formulations in a single-dose, double-blind, randomized 4-way cross-over design. The formulations were three study drugs with different extended dissolution rates (ER1Tab, ER2Tab and ER3Caps ) and one reference drug (LR). Urinary volume and contents of frusemide in urine were measured in samples collected over 24 h. RESULTS: Substantial differences in frusemide recovery and diuretic efficiency were observed between LR and all other formulations. At 24 h, mean total frusemide recoveries of ER1Tab, ER2Tab and ER3Caps were 52%, 36% and 57% lower, respectively, compared with LR (P<0.01). Also at 24 h, mean total diuretic efficiency for ER1Tab, ER2Tab and ER3Caps was 83%, 31% and 135% higher, respectively, compared to LR. The rapid dissolution and absorption of LR resulted in a high diuretic response from 0 to 3 h after dosing. However, from 0 to 24 h, there were no differences in diuretic response between the formulations. CONCLUSIONS: Controlled release formulations of frusemide with a low and extended rate of dissolution lead to a more prolonged absorption and subsequent diuresis, but still maintain a similar cumulative response, due to their higher diuretic efficiency. (+info)